OncoMed Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapeutics that address the fundamental biology driving cancer's growth, resistance, recurrence and metastasis. To date, we have advanced nine novel anti-cancer product candidates into more than 14 IND's, initiated 27 clinical studies and have enrolled more than 1,300 subjects. We continue to pursue the discovery of additional novel anti-cancer therapeutics. All of our product candidates were discovered internally in our own research laboratories.
As our understanding of the biologic pathways driving tumor growth, metastases and recurrence has increased, new discoveries from our research team have identified novel immuno-oncology targets. Tumor cells have evolved ways of evading the body's immune system in order to grow. The therapeutic candidates in our pipeline act by blocking those evasive techniques, making tumor cells more visible to immune system attack and/or bolstering targeted immune cell activity. We are also deploying our expertise in the engineering of antibodies to create new bispecifics that contain two potential drugs in one antibody and are designed to increase anti-cancer activity and in some cases, mitigate known off-target effects. We believe each of our distinct therapeutic candidates has the potential to significantly impact cancer treatment and the clinical outcome of patients with cancer.
To support the advancement of our pipeline and our continued discovery efforts, OncoMed has assembled a proven management team with expertise in oncology research, drug discovery, clinical development, translational medicine, regulatory affairs, and commercial development. In addition, we have established an extensive patent portfolio protecting our novel product candidates, as well as our platform R&D technologies. We have formed strategic alliances with companies such as Celgene Corporation and Bayer Pharma AG. Since our founding in August 2004, we have raised more than $600 million, more than half of which has come from collaboration funding from our pharmaceutical partnerships, with the rest consisting of equity financings, including an Initial Public Offering in 2013.